Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC)

Pirker, Robert; Krajnik, G.; Zöchbauer, S.; Malayeri, R.; Mp, Kneussl; Huber, H.

doi:10.1093/oxfordjournals.annonc.a059324

Cited by 52 publications

(23 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inclusion of these agents in combination chemotherapy regimens may provide a substantial improvement in the treatment of this disease. Pirker et al (1995) (1998) 78(2), [251][252][253][254][255][256] carboplatin in 53 patients with advanced NSCLC. In contrast, Johnson et al (1996) used the same paclitaxel and carboplatin combination and obtained a relatively disappointing response rate of 27%, a median survival time of 38 weeks, and a 1-year survival of 32% in patients with stage IV NSCLC.…”

Section: Discussionmentioning

confidence: 99%

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer

Masuda

Fukuoka²,

Fujita³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary A phase trial of the combination of irinotecan (CPT-11) with cisplatin in advanced non-small cell lung cancer (NSCLC) showed a very promising response rate of 54% in previously untreated NSCLC patients. This study was conducted to confirm the activity and toxicities of CPT-11 and cisplatin combination for previously untreated NSCLC in a multi-institutional phase 11 study. Seventy patients with stage IIIB or IV NSCLC received CPT-11 60 mg m-2 intravenously (IV) on days 1, 8 and 15, and cisplatin 80 mg m-2 (IV) on day 1 every 4 weeks. Assessments were made of response, survival and toxicities. Sixty-nine were eligible, and evaluable for toxicities and survival, and 64 patients evaluable for response. Thirty-three patients (52%; 95% confidence interval 39-64%) achieved an objective response, with one complete response (2%) and 32 partial responses (50%). The median duration of response was 19 weeks and the overall median survival time was 44 weeks. The 1-year survival rate was 33%. The major toxic effects were leucopenia and diarrhoea. Grade 3 or 4 leucopenia, neutropenia, and diarrhoea occurred in 32 patients (46%), 53 patients (80%), and 13 patients (19%) respectively. A combination of CPT-11 and cisplatin is very effective against non-small-cell lung cancer with acceptable toxicities.

show abstract

Section: Discussionmentioning

confidence: 99%

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer

Masuda

Fukuoka²,

Fujita³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Nonetheless, several randomized trials have shown that, compared with the best supportive care, cisplatin-based chemotherapy improves median survival and quality of life in patients with advanced NSCLC [10, 11, 12, 13, 14, 15]. Moreover, paclitaxel, a new chemotherapeutic agent with high activity in non-small-cell lung cancer [16, 17, 18, 19], in combination with cisplatin has shown response rates ranging from 31 to 56% [20, 21], which is higher than those observed with paclitaxel or cisplatin alone. Two phase III trials conducted in Europe and the United States which compared paclitaxel-cisplatin with either cisplatin-teniposide or cisplatin-etoposide showed the superiority of the first combination.…”

Section: Introductionmentioning

confidence: 99%

Front-Line Paclitaxel/Cisplatin-Based Chemotherapy in Brain Metastases from Non-Small-Cell Lung Cancer

Cortés¹,

Rodríguez²,

Aramendía³

et al. 2002

Oncology

119

View full text Add to dashboard Cite

Objective: Paclitaxel-cisplatin is considered to be a standard therapy for metastatic non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the activity and toxicity of this combination with vinorelbine or gemcitabine as front-line therapy in brain metastases from NSCLC. Methods: Twenty-six chemotherapy-naive patients with an ECOG performance status of 0–2 were treated with paclitaxel (135 mg/m²) on day 1, cisplatin (120 mg/m²) on day 1, and either vinorelbine (30 mg/m²) on days 1 and 15 or gemcitabine (800 mg/m²) on days 1 and 8. Whole-brain irradiation was offered early in case of progression and later as consolidation treatment. Results: All patients were evaluated for toxicity and 25 for response. An intracranial response rate was observed in 38% of the patients (95% CI: 22–59%). WHO grade 3–4 neutropenia and thrombocytopenia occurred in 31 and 4% of the patients, respectively. There was one treatment-related death. Non-hematological toxicities were mild. After a median follow-up of 46 months, the median overall survival for all patients was 21.4 weeks and the median time to progression was 12.8 weeks. Conclusions: Paclitaxel and cisplatin combined with vinorelbine or gemcitabine as front-line therapy in brain metastases seem to achieve responses similar to those for extracranial disease, suggesting a meaningful role in this setting.

show abstract

“…Examples of effective combinations include gemcitabine plus cisplatin (response rates of 30-54% and median survivals of 13-66 weeks (Abratt et al, 1997;Crino et al, 1997;Sandler et al, 2000)), paclitaxel plus cisplatin (response rates of 41-47% and an estimated median survival of 43 weeks (Klastersky and Sculier, 1995;Pirker et al, 1995;Giaccone et al, 1998b)), paclitaxel plus carboplatin (response rates from 27% to 62%, a median survival of 34.3-56.7 weeks and a 1-year survival of 32-54% depending on the dosing schedule of paclitaxel (Langer et al, 1995;Johnson et al, 1996;Hainsworth et al, 1998)), and navelbine plus cisplatin (a response rate of 43% and a median survival of 35.3 weeks (Depierre et al, 1994)). However, the emergence of new agents with superior singleagent activity to cisplatin and carboplatin has presented an opportunity to investigate the efficacy and safety of non-platinumcontaining combinations in this clinical setting (Lilenbaum and Green, 1993).…”

Section: Discussionmentioning

confidence: 99%

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study

et al. 2001

View full text Add to dashboard Cite

The efficacy and toxicity of combined paclitaxel and gemcitabine was evaluated in 54 chemotherapy-naive patients with metastatic non-small cell lung cancer (NSCLC). Gemcitabine i.v. 1000 mg/m 2 was administered on days 1 and 8 and paclitaxel 200 mg/m 2 as a continuous 3-hour infusion on day 1. Treatment was repeated every 21 days. Patients had a median age of 53 years. ECOG performance status was 0 or 1 in 48 patients. 41 patients (75.9%) had initial stage IV disease; histology was mainly adenocarcinoma (46.3%). 2 patients (4.3%) achieved a complete response and 15 (31.9%) achieved a partial response giving an overall response rate of 36.2% (95% CI: 22.4–49.9%); 19 patients (40.4%) had stable disease and 10 (21.3%) had progressive disease. The median survival time was 51 weeks (95% CI: 46.5–59.3), with a 1-year survival probability of 0.48 (95% CI: 0.34–0.63). Grade 3/4 neutropenia and febrile neutropenia occurred in 15.2% and 2.2% of courses, respectively. Grade 3/4 thrombocytopenia was rare (1.8% of courses). Peripheral neurotoxicity developed in 25 patients (47.2%), mostly grade 1/2. Arthalgia/myalgia was observed in 30 patients (56.6%), generally grade 1 or 2. Grade 3 abnormal levels of serum glutamate pyruvate transaminase (SGPT) and serum glutamate oxaloacetate transaminase (SGOT) occurred in 5 patients (9.4%) and 1 patient (1.9%), respectively. Combined paclitaxel and gemcitabine is an active and well-tolerated regimen for the treatment of advanced NSCLC, and warrants further investigation in comparative, randomized trials. © 2001 Cancer Research Campaign http://www.bjcancer.com

show abstract

Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC)

Cited by 52 publications

References 10 publications

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer

Front-Line Paclitaxel/Cisplatin-Based Chemotherapy in Brain Metastases from Non-Small-Cell Lung Cancer

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study

Contact Info

Product

Resources

About